Amendments to oral cancers bill would increase co-pay for oral tumor treatment.

If exceeded, the amended edition would still need to be approved by the Condition Assembly by the end of the program this Friday, 6th September, and signed by Governor Jerry Brown before it becomes law then. We congratulate Assemblyman Perea on piecing together a bill that may surely come nearly as good news for some patients with very high co-pays, said Larry Lanier, NPAF President. However, a $200 co-pay out cap that is linked with annual increases continues to be too high for most patients who already are being forced to abandon their tumor treatment due to prohibitive price. From the first time, our mission has been to serve as the voice and advocate for all individuals battling illnesses, particularly those who often have not the strength or assets to champion their own cause. We ask Governor Brown and California state lawmakers to stand with us and recognize the power given to so many people with cancer by preserving the $100 co-pay for oral chemo lacking any annual cost increase, said Davenport-Ennis..The full total study is likely to enroll a total of about 880 head and neck cancer sufferers in about 48 hospitals in 9 countries on three continents. CEL-SCI’s partners Teva Pharmaceuticals and Orient Europharma will conduct parts of the Phase III research in Israel and Taiwan respectively. The goal of this research is to establish Multikine as a first-line regular of care and attention therapy in treating newly diagnosed, not yet treated head and neck cancer patients. The trial is thought to be the biggest head and neck tumor research ever conducted and is called ‘IT-MATTERS’, an acronym for: Immunotherapy Multikine Anti Tumor Treatments. ‘We are very excited to do this pivotal research in the first center outside of the US,’ said Geert Kersten, Chief Executive Officer of CEL-SCI.